RCT: Rituximab vs. tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial – The Lancet

Commentary: Precision medicine in rheumatology: are we getting closer? – The Lancet

Commentary on Twitter

For patients with rheumatoid #arthritis and low or absent B-cell lineage expression signature in synovial tissue, tocilizumab is more effective than rituximab, suggests the first biopsy-driven trial. Read the results in full: https://t.co/XjzOqeBwdc pic.twitter.com/hODUwDy8BP

— The Lancet (@TheLancet) January 26, 2021